Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
Abstract Cyclin dependent kinase 2 (CDK2) regulates cell cycle and is an emerging target for cancer therapy. There are relatively small numbers of tumor models that exhibit strong dependence on CDK2 and undergo G1 cell cycle arrest following CDK2 inhibition. The expression of P16INK4A and cyclin E1...
Saved in:
Main Authors: | Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, Yin Wan, Adam P. Dommer, Hanna Rosenheck, Sivasankar Putta, Alec Trub, John Bisi, Jay Strum, Patrick Roberts, Seth M. Rubin, Costakis Frangou, Karen McLean, Agnieszka K. Witkiewicz, Erik S. Knudsen |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-025-56674-4 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CDK14 regulates the development and repair of lung
by: Jian-wei Chen, et al.
Published: (2025-01-01) -
Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
by: Marta Buzzetti, et al.
Published: (2021-03-01) -
Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
by: Yilan Yang, et al.
Published: (2025-02-01) -
Cdk6’s functions are critically regulated by its unique C-terminus
by: Alessia Schirripa, et al.
Published: (2025-02-01) -
Author Correction: Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
by: Marta Buzzetti, et al.
Published: (2025-02-01)